AI Article Synopsis
- An observational cost analysis was conducted to compare the Mark Cuban Cost Plus Drug Company (CostPlus) with GoodRx.
- The study focused on the economics of prescription medications, particularly in the field of dermatology.
- Results indicated that CostPlus could potentially reduce the financial burden of these medications for patients.
Article Abstract
This observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661688 | PMC |
| http://dx.doi.org/10.2196/64300 | DOI Listing |
Publication Analysis
Top Keywords
mark cuban
8
cuban cost
8
cost drug
8
drug company
8
improving affordability
4
affordability dermatology
4
cost
4
dermatology cost
4
cost savings
4
savings mark
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!